-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Intelligent Non-invasive Diagnosis of Aneuploidy: Raw Values and Highly Imbalanced Dataset.
Neocleous A, Nicolaides K, Schizas C.
IEEE J Biomed Health Inform 2017;21:1271-1279. pdf -
ISUOG Practice Guidelines: role of ultrasound in twin pregnancy.
Khalil A, Rodgers M, Baschat A, Bhide A, Gratacos E, Hecher K, Kilby MD, Lewi L, Nicolaides KH, Oepkes D, Raine-Fenning N, Reed K, Salomon LJ, Sotiriadis A, Thilaganathan B, Ville Y.
Ultrasound Obstet Gynecol 2016;47:247-63. pdf -
First Trimester Noninvasive Prenatal Diagnosis: A Computational Intelligence Approach.
Neocleous AC, Nicolaides KH, Schizas CN.
IEEE J Biomed Health Inform 2016;20:1427-38. pdf -
Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:247-61. -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Nasal bone assessment in fetuses with trisomy 21 at 16-24 weeks of gestation by three-dimensional ultrasound.
Persico N, Molina F, Azumendi G, Fedele L, Nicolaides KH.
Prenat Diagn 2012;32:240-4. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Nasal bone length in euploid fetuses at 16-24 weeks of gestation by three-dimensional ultrasound.
Persico N, Molina F, Borenstein M, Azumendi G, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:285-90. -
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:259-64. -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Nasal bone assessment in prenatal screening for trisomy 21.
Sonek JD, Cicero S, Neiger R, Nicolaides KH.
Am J Obstet Gynecol 2006;195:1219-30. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH.
Am J Obstet Gynecol 2004;191:45-67. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5. -
Nasal bone hypoplasia in trisomy 21 at 15-22 weeks' gestation.
Cicero S, Sonek JD, McKenna DS, Croom CS, Johnson L, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;21:15-8. -
Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome.
Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2002;186:139-41.